Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →"Bayer believes a small biotech in England has a blockbuster drug for menopause patients"; NT-814 "has the potential to be first drug of its kind to reach the…
Bayer's $425M upfront / up to $875M total deal positions the company to challenge Astellas' fezolinetant (Phase 3 NK3 antagonist) for the menopause market,…
NT-814 is a non-hormonal, orally administered, potent and selective small molecule dual NK1/NK3 antagonist modulating the KNDy neurones; Bayer projects peak…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Bayer acquired KaNDy Therapeutics for $425M upfront plus up to $450M in success-based milestones plus triple-digit million sales milestones. Lead asset NT-814 (now elinzanetant) is a dual NK-1/NK-3 receptor antagonist for menopausal vasomotor symptoms.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / KaNDy Therapeutics Ltd. (this deal) | 2019 | $875M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2019 deals · Bayer AG deals · Women's Health deals